
|Articles|September 1, 2003
Fungoides Foiler
San Francisco - Cytokine therapies that enhance the T-helper 1 (TH1) response may be the key to effective treatment of mycosis fungoides, according to David P. Fivenson, M.D. The treatments, still in the investigative stage, have potential advantages over existing treatments because their selectivity of action also reduces the risk of nonselectivity-related toxicity, he said, noting that mycosis fungoides is now typically termed cutaneous T-cell lymphoma.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
4
Moving Past Dermal Filler Trends to Focus on Healthy Skin Aging
5














